Overview
Lin Rui is a senior partner at Eight Roads Capital and co-head of the China Healthcare Fund. She has led investments in leading companies in various industries such as Beijing Yingshuoli Technology (acquired by Hologic, Inc.), Haili Biotech (SH 603718), Jianyou (SH 603707), Aibo Medical (SH 688050), Gushengtang (HK 02273), Sipai Health (HK 00314) and Banger Orthopedics. Joined Eight Roads Venture Capital China team in. Bachelor's degree in Economics from Shenzhen University and MBA from the Wharton School of the University of Pennsylvania; previously worked at CMT ChinaValue Capital Partners, Vision Capital China, A.T. Kearney, and Arthur Andersen (2007).
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
林蕊是斯道资本资深合伙人兼中国医疗基金联合主管。她主导投资了北京英硕力科技（被Hologic, Inc.收购）、海利生物（SH 603718）、健友股份（SH 603707）、爱博医疗（SH 688050）、固生堂（HK 02273）、思派健康（HK 00314）以及邦尔骨科等各行业的领先企业。2007年加入斯道资本风险投资中国团队。深圳大学经济学学士、美国宾夕法尼亚大学沃顿商学院工商管理硕士；曾任职CMT ChinaValue Capital Partners、Vision Capital China、科尔尼管理咨询公司（A.T. Kearney）、安达信会计师事务所（Arthur Andersen）。